Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Top Cited Papers
- 30 June 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (7)
- https://doi.org/10.1128/AAC.00819-20
Abstract
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.Funding Information
- National Research Foundation of Korea (NRF-2017M3A9G6068245, NRF-2020M3E9A1041756)
This publication has 16 references indexed in Scilit:
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaThe New England Journal of Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning modelPublished by Cold Spring Harbor Laboratory ,2020
- SLEW OF TRIALS LAUNCH TO TEST CORONAVIRUS TREATMENTS IN CHINANature, 2020
- SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infectionNature Communications, 2019
- Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthmaJournal of Asthma and Allergy, 2009
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by NiclosamideAntimicrobial Agents and Chemotherapy, 2004
- Absorption of pyrvinium pamoateClinical Pharmacology & Therapeutics, 1976